KEGG   DRUG: Volrustomig
Entry
D12347                      Drug                                   
Name
Volrustomig (USAN)
Formula
C6528H10050N1736O2026S47
Exact mass
146682.3624
Mol weight
146773.1172
Sequence
(A chain)
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV IWYDGSNKYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDP RGATLYYYYY GMDVWGQGTT
VTVSSASTKG PSVCPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KRVEPKSVDK THTCPPCPAP
EFEGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPASI EKTISKAKGQ PREPQVYTLP
PCREEMTKNQ VSLWCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
(B chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYGMHWVRQA PGKGLEWVAY ISSGSYTIYS
ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARRA PNSFYEYYFD YWGQGTTVTV
SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPEFE
GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPASIEKT ISKAKGQPRE PQVCTLPPSR
EEMTKNQVSL SCAVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LVSKLTVDKS
RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK
(C chain)
QIVLTQSPAT LSLSPGERAT LSCSASSKHT NLYWSRHMYW YQQKPGQAPR LLIYLTSNRA
TGIPARFSGS GSGTDFTLTI SSLEPEDFAV YYCQQWSSNP FTFGQGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(D chain)
DIQMTQSPSS LSASVGDRVT ITCRASQSIN SYLDWYQQKP GKAPKLLIYA ASSLQSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YYSTPFTFGP GTKVEIKGQP KAAPSVTLFP
PCSEELQANK ATLVCLISDF YPGAVTVAWK ADSSPVKAGV ETTTPSKQSN NKYAASSYLS
LTPEQWKSHR SYSCQVTHEG STVEKTVAPT EVS
(Disulfide bridge: A22-A96, A134-D122, A152-A208, A234-B231, A237-B234, A269-A329, A362-A354, A375-A433, B22-B96, B149-B205, B225-C219, B266-B326, B372-B430, C23-C93, C139-C199, D23-D88 D135-D194)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immune checkpoint inhibitor
Comment
Monoclonal antibody; bispecific antibody
Target
CTLA4 (CD152) [HSA:1493] [KO:K06538]
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12347  Volrustomig
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    CTLA4 (CD152)
     D12347  Volrustomig (USAN)
    PDCD1 (PD1, CD279)
     D12347  Volrustomig (USAN)
Other DBs
CAS: 2407760-40-9
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system